Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 7:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 7,072 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Mammary Cancer Clear all
Completed Phase 3 Interventional Results available

Study Comparing Whole Breast Radiotherapy With a Daily Versus a Weekly Tumor

NCT01000662
View directory record Official record
Conditions
Breast Cancer
Interventions
Daily Radiation Therapy, Weekly Radiation Therapy
Radiation
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Female only
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 6, 2020 · Synced Oct 24, 2026, 7:45 AM EDT
Terminated No phase listed Observational

EndoPredict® Extended Endocrine Trial (EXET)

NCT04016935
View directory record Official record
Conditions
Primary Invasive Breast Cancer
Interventions
Observational
Other
Lead sponsor
Myriad Genetic Laboratories, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
855 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
52
States / cities
Burbank, California • Roseville, California • Fort Myers, Florida + 40 more
Source: ClinicalTrials.gov public record
Updated May 17, 2022 · Synced Oct 24, 2026, 7:45 AM EDT
Completed Not applicable Interventional

Emerging From the Haze™- Measuring the Impact of a Psycho-education Program on Perceived Cognition After Breast Cancer Treatment

NCT02360917
View directory record Official record
Conditions
Cognition, Cancer
Interventions
Emerging from the Haze
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 1, 2018 · Synced Oct 24, 2026, 7:45 AM EDT
Completed Not applicable Interventional Results available

Promoting Breast Cancer Screening in Women Who Survived Childhood Cancer

NCT03435380
View directory record Official record
Conditions
Breast Neoplasms, Early Detection of Cancer
Interventions
Patient activation, Primary care physician activation, Control
Behavioral
Lead sponsor
Duke University
Other
Eligibility
25 Years and older · Female only
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
5
States / cities
New York, New York • Durham, North Carolina • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 8, 2023 · Synced Oct 24, 2026, 7:45 AM EDT
Active, not recruiting No phase listed Observational

IORT-Breast at Medical Center Navicent Health

NCT04595435
View directory record Official record
Conditions
Breast Cancer Female, Early-stage Breast Cancer
Interventions
Lumpectomy, Intraoperative Radiation Therapy
Procedure · Radiation
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
55 Years and older · Female only
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2033
U.S. locations
1
States / cities
Macon, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 24, 2026, 7:45 AM EDT
Active, not recruiting Not applicable Interventional

Trial to Compare MRI-guided Precision Prone Irradiation (PPI) Versus CT-guided Breast Irradiation

NCT05731791
View directory record Official record
Conditions
Breast Cancer
Interventions
Radiation Therapy to partial breast
Radiation
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
50 Years to 90 Years · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2034
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 24, 2026, 7:45 AM EDT
Completed Phase 2 Interventional Results available

Neoadjuvant Study of Two Platinum Regimens in Triple Negative Breast Cancer

NCT02413320
View directory record Official record
Conditions
Triple-negative Breast Cancer
Interventions
Paclitaxel, Carboplatin, Doxorubicin, Cyclophosphamide, Docetaxel
Drug
Lead sponsor
Priyanka Sharma
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
9
States / cities
Fairway, Kansas • Hays, Kansas • Overland Park, Kansas + 4 more
Source: ClinicalTrials.gov public record
Updated May 10, 2021 · Synced Oct 24, 2026, 7:45 AM EDT
Completed No phase listed Observational

Self-Reported Exercise Behavior and Short-Term Patient Outcomes in Women Undergoing Radiation Treatment for Operable Breast Cancer

NCT02050620
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 3, 2015 · Synced Oct 24, 2026, 7:45 AM EDT
Completed Phase 1 Interventional

Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer

NCT05712889
View directory record Official record
Conditions
Neoplasms
Interventions
VIP236 (Q3W), VIP236 (Q2W)
Drug
Lead sponsor
Vincerx Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
3
States / cities
Scottsdale, Arizona • Austin, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 15, 2024 · Synced Oct 24, 2026, 7:45 AM EDT
Completed Not applicable Interventional Results available

Implementing BREASTChoice Into Practice

NCT04491591
View directory record Official record
Conditions
Breast Reconstruction, Breast Cancer
Interventions
Breast Reconstruction Education and Support Tool (BREASTChoice), Attention Control Website, Clinician Survey
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
St Louis, Missouri • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 12, 2024 · Synced Oct 24, 2026, 7:45 AM EDT
Completed No phase listed Observational

Developing Mouse Models of Breast Cancer Using Tissue Samples From Women With Breast Cancer

NCT00897468
View directory record Official record
Conditions
Breast Cancer
Interventions
laboratory biomarker analysis, medical chart review
Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 4, 2018 · Synced Oct 24, 2026, 7:45 AM EDT
Completed Phase 2 Interventional Results available

Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer

NCT01959490
View directory record Official record
Conditions
Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
trastuzumab, Pertuzumab, docetaxel, carboplatin, doxorubicin, cyclophosphamide, paclitaxel, Bevacizumab
Biological · Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Oct 24, 2026, 7:45 AM EDT
Terminated Phase 1 Interventional

Eniluracil Hand Foot Syndrome

NCT00827580
View directory record Official record
Conditions
Breast Cancer, Colon Cancer
Interventions
Eniluracil
Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated May 30, 2018 · Synced Oct 24, 2026, 7:45 AM EDT
Completed Phase 2 Interventional

Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery

NCT03113825
View directory record Official record
Conditions
Primary Invasive Malignant Neoplasm of Female Breast, Carcinoma Breast, Breast Cancer Female, Carcinoma, Ductal, Breast, Stage II Breast Cancer, Stage I Breast Cancer, Stage III Breast Cancer
Interventions
Investigational Imaging device, AVB-620
Device · Drug
Lead sponsor
Avelas Biosciences, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
13
States / cities
San Diego, California • Washington D.C., District of Columbia • Jacksonville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 24, 2026, 7:45 AM EDT
Terminated Phase 1Phase 2 Interventional

MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma.

NCT00147550
View directory record Official record
Conditions
Melanoma, Colonic Neoplasms, Breast Neoplasms
Interventions
PD-0325901
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
17
States / cities
Birmingham, Alabama • La Jolla, California • La Mesa, California + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2013 · Synced Oct 24, 2026, 7:45 AM EDT
Completed Phase 1Phase 2 Interventional

Liposomal Doxorubicin and Trastuzumab in Treating Women With Advanced Breast Cancer

NCT00006825
View directory record Official record
Conditions
Breast Cancer
Interventions
trastuzumab, pegylated liposomal doxorubicin hydrochloride
Biological · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 28, 2011 · Synced Oct 24, 2026, 7:45 AM EDT
Completed Not applicable Interventional

An Intervention to Decrease Fatigue Among Breast Cancer Survivors

NCT00273208
View directory record Official record
Conditions
Fatigue After Adjuvant Breast Cancer Treatment
Interventions
10 week behavioral intervention program
Behavioral
Lead sponsor
Mercy Medical Center
Other
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 2, 2007 · Synced Oct 24, 2026, 7:45 AM EDT
Approved For Marketing No phase listed Expanded access

An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic

NCT04395508
View directory record Official record
Conditions
HER2-positive Breast Cancer
Interventions
Pertuzumab and Trastuzumab Fixed-Dose Combination for Subcutaneous Administration (PH FDC SC)
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
12
States / cities
Beverly Hills, California • San Francisco, California • Stanford, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2022 · Synced Oct 24, 2026, 7:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Enhancing At-risk Latina Women's Use of Genetic Counseling for Hereditary Breast and Ovarian Cancer

NCT03075540
View directory record Official record
Conditions
Hereditary Breast and Ovarian Cancer
Interventions
Genetic Counseling and Testing YouTube Video
Behavioral
Lead sponsor
Georgetown University
Other
Eligibility
21 Years and older · Female only
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Alexandria, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Oct 24, 2026, 7:45 AM EDT
Completed Phase 1 Interventional Results available

Risk-Guided Cardioprotection With Carvedilol in Breast Cancer Patients Treated With Doxorubicin and/or Trastuzumab

NCT04023110
View directory record Official record
Conditions
Cardiotoxicity, Risk Factor, Cardiovascular, Toxicity Due to Chemotherapy, Breast Cancer, Cardiomyopathies, Heart Failure
Interventions
Carvedilol
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Oct 24, 2026, 7:45 AM EDT
Active, not recruiting Phase 1 Interventional

PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer

NCT03362060
View directory record Official record
Conditions
Triple Negative Breast Cancer, Metastatic Breast Cancer
Interventions
Pembrolizumab, PVX-410
Drug · Biological
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 24, 2026, 7:45 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

FLASH-Breast: Evaluating the Efficacy of Fezolinetant in Reducing Vasomotor Symptoms in Women With Breast Cancer on Endocrine Therapy

NCT06917313
View directory record Official record
Conditions
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Interventions
Fezolinetant, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Female only
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
2
States / cities
New Haven, Connecticut • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 24, 2026, 7:45 AM EDT
Completed Not applicable Interventional

Gabapentin For the Control of Hot Flashes in Women With Breast Cancer

NCT00022074
View directory record Official record
Conditions
Anxiety Disorder, Breast Cancer, Depression, Hot Flashes
Interventions
gabapentin, quality-of-life assessment
Drug · Procedure
Lead sponsor
Gary Morrow
Other
Eligibility
Up to 120 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
18
States / cities
Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2015 · Synced Oct 24, 2026, 7:45 AM EDT
Active, not recruiting Not applicable Interventional

A Study of the Use of Text Message Reminders to Take Palbociclib

NCT04216576
View directory record Official record
Conditions
Breast Cancer
Interventions
Paper Drug Diary, OhMD APP
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 24, 2026, 7:45 AM EDT